Shepherd CEO David Hysong Named To "Forbes 30 Under 30: Healthcare"

SHEPHERD Founder and CEO David Hysong (29) was named a member of Forbes 30 Under 30 Class of 2017, honoring "the brightest young entrepreneurs, breakout talents and change agents in 20 different sectors." Hysong was selected for the Healthcare sector, joining a class boasting a United Nations commissioner, postdoctoral fellows at the nation's best medical schools, and several healthcare company founders.

Before being diagnosed with Adenoid Cystic Carcinoma -- a rare and untreatable head-and-neck cancer -- Hysong investigated the sexual enslavement of children in Cambodia, studied at Harvard Divinity School, and trained for the U.S. special armed forces. After learning about his own disease and meeting many rare cancer patients faced with the concerns as him, Hysong founded SHEPHERD, a biotech company focused on finding treatments for rare cancers. In 2016, Hysong assembled a team of experts in the field and raised $6.5 million in angel investments.

"Thank you to Forbes and everyone who made this possible, especially the SHEPHERD team," Hysong says. "I am humbled and incredibly energized to be chosen for the Forbes 30 Under 30 Class of 2017. SHEPHERD made great strides in 2016 and making the Forbes list is an encouraging affirmation of that. In 2017, I look forward to continue fighting for our mission of saving the life of every individual with rare cancer."

About SHEPHERD:

The mission of SHEPHERD is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a biotechnology company relentlessly focused on using deep disease understanding, development expertise, and an unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.